---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-041543"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2026-06-08T20:10:17+00:00"
generated_at: "2026-06-08T20:17:12.200359+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine shareholders elect directors, ratify auditor at 2026 annual meeting

## Summary
- Michael Kelly elected Class I director: 107,059,058 for, 3,047,945 withheld, 30,277,721 broker non-votes.
- David Schenkein, M.D. elected Class I director: 87,522,409 for, 22,584,594 withheld, 30,277,721 broker non-votes.
- Ratification of PricewaterhouseCoopers as auditor approved: 139,989,201 for, 101,259 against, 294,264 abstain.

## SEC filing metadata
- accession: 0001628280-26-041543
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2026-06-08T20:10:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/0001628280-26-041543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/prme-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-041543
- JSON: https://secwatch.observer/filing/0001628280-26-041543.json
- Plain text: https://secwatch.observer/filing/0001628280-26-041543.txt

## Key facts
- Shareholder Votes
  Prime Medicine, Inc. shareholders approved To elect Michael Kelly and David Schenkein, M.D. as Class I Directors. at the 2026-06-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 9, 2026, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 180,615,889. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 140,384,724, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common St
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/0001628280-26-041543-index.htm
- Shareholder Votes
  Prime Medicine, Inc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 9, 2026, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 180,615,889. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 140,384,724, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common St
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/0001628280-26-041543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.